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Available online 14 May 2012Abstract Umbilical cord blood (UCB) transplantation has emerged as a promising therapy, but it is challenged by scarcity of
stem cells. Eltrombopag is a non-peptide, thrombopoietin (TPO) receptor agonist, which selectively activates c-Mpl in humans
and chimpanzees. We investigated eltrombopag's effects on human UCB hematopoietic stem cell (HSC) and hematopoietic
progenitor cell (HPC) expansion, and its effects on hematopoiesis in vivo. Eltrombopag selectively augmented the expansion of
human CD45+, CD34+, and CD41+ cells in bone marrow compartment without effects on mouse bone marrow cells in the NOD/
SCID mice xenotransplant model. Consequently, eltrombopag increased peripheral human platelets and white blood cells. WeAbbreviations: FBS, fetal bovine serum; FL, flt-3 ligand; G (M)-CSF, granulocyte (macrophage) colony-stimulating factor; GVHD, graft
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78 H. Sun et al.further examined effects in the STAT and AKT signaling pathways in serum-free cultures. Eltrombopag expanded human CD34+
CD38−, CD34+, and CD41+ cells. Both eltrombopag and recombinant human TPO (rhTPO) induced phosphorylation of STAT5
of CD34+ CD41−, CD34− CD41+, and CD34− CD41− cells. rhTPO preferentially induced pSTAT3, pAKT, and more pSTAT5 in CD34
− C41+ cells, while eltrombopag had no effects on pSTAT3. In conclusion, eltrombopag enhanced expansion of HSCs/HPCs of
human UCB in vivo and in vitro, and promoted multi-lineage hematopoiesis through the expansion of bone marrow HSCs/HPCs
of human UCB in vivo. Eltrombopag differed somewhat from rhTPO in the signal transduction pathways by favoring earlier HSC/
HPC populations.
Published by Elsevier B.V.Introduction
Umbilical cord blood transplantation (UCBT) holds great
promise with apparent clinical advantages, but the trans-
plant success rate remains much poorer than peripheral
blood stem cell (PBSC) or bone marrow stem cell sources.
This is due to the scarcity of stem cells in each unit, thus ex
vivo expansion of UBC continues to be an area of active
research (Koestenbauer et al., 2009). Nonetheless, human
UCB stem cells are useful for patients without matched
related or unrelated donors, because an estimated 40%–80%
of patients will not be able to find an acceptable adult stem
cell donor for stem cell transplantation (Ballen et al., 2007;
Barker et al., 2003; Brunstein et al., 2007; Misawa et al.,
2006; Rocha et al., 2009). Human UCB offers practical
advantages as an alternative source of bone marrow stem
cell or PBSC, which include (1) the relative ease of
procurement (ability to store fully tested and HLA-typed
UCB available for immediate use); (2) the absence of risk to
the mother and the donors; (3) the reduced likelihood of
transmitting infections; (4) immaturity of immune cells, thus
reduced risk of GVHD; (5) less stringent criteria for HLA
matching for donor–recipient selection (with the potential
of finding donors for minority populations); (6) absence of
donor attrition (Chao et al., 2004); and (7) availability: UCB
banks have been established for related and unrelated UCB
transplantation with more than 100,000 units being avail-
able based on published data (Barker et al., 2002; Gluckman
et al., 2001; Kernan et al., 1993; Rocha et al., 2000). Thus
agents that can facilitate human UCB hematopoietic stem
cell (HSC) and hematopoietic progenitor cell (HPC) expan-
sion are highly desirable.
The cytokine thrombopoietin (TPO) plays a crucial role
in thrombopoiesis, in the regulation of HSCs, and in the
proliferation of primitive HPCs. Both murine and human HSCs
are highly enriched in cells expressing the TPO receptor c-Mpl
(Solar et al., 1998; Yoshihara et al., 2007). Administration of
TPO to myelosuppressed animals not only significantly allevi-
ates thrombocytopenia, but also accelerates multiple lineage
recovery (Akahori et al., 1996; Farese et al., 1996; Grossmann
et al., 1996a, 1996b; Kaushansky et al., 1996; Neelis et al.,
1997), promotes the reconstitution of multiple-lineage imma-
ture progenitors/precursors in bonemarrow and spleen (Farese
et al., 1996; Grossmann et al., 1996a; Kaushansky et al., 1996;
Neelis et al., 1997), and augments the responses to GM-CSF and
G-CSF (Farese et al., 1996; Grossmann et al., 1996a; Neelis
et al., 1997). In vitro, TPO acts alone and most effectively in
synergy with other early cytokines to promote survival and
proliferation of HSCs and HPCs, and supports their expansion
and differentiation into multiple-lineage colony-forming pro-
genitors (Borge et al., 1997; Kobayashi et al., 1996; Ku et al.,1996; Luens et al., 1998; Ramsfjell et al., 1997; Petzer et al.,
1996; Sitnicka et al., 1996; Young et al., 1996). TPO is also
known to be critical for the replenishment of HSCs after bone
marrow transplantation (Fox et al., 2002; Qian et al., 2007).
These observations established the crucial roles of TPO
receptor (c-Mpl) signaling on not only megakaryocytopoiesis,
but also early hematopoiesis including regulation of HSCs.
While TPO holds promise in thrombopoiesis and in promoting
stem cell proliferation and differentiation, phase II–III clinical
trials of rhTPO and its shorter polyethylene glycol-conjugated
form, PEG-rHuMGDF yielded mixed results. This was due to the
fact that both were associated with autoantibodies that cross-
reacted with and neutralized endogenous TPO, ultimately
leading to low platelet counts. Clinical trials of these agents
were discontinued in the United States several years ago
(Basser et al., 2002; Li et al., 2001). Since then, a peptide
mimetic (romiplostim), and a few non-peptide, small molecule
c-Mpl agonists have been developed as alternatives to
recombinant TPO (Erickson-Miller et al., 2009; Fukushima-
Shintani et al., 2009; Inagaki et al., 2004; Nakamura et al.,
2006; Nogami et al., 2008). Among these, eltrombopag (SB-
497115) is an oral thrombopoietic receptor agonist, which
interacts with the transmembrane domain of the c-Mpl. The
latter confers unique species-specificity of eltrombopag, which
binds to c-Mpl of humans and chimpanzees only (Erickson-Miller
et al., 2005, 2009). Eltrombopag selectively activates the c-Mpl
signaling pathway, stimulates the growth of TPO-dependent cell
lines, promotes isolated human CD34+ cells to become mega-
karyocytes, and increases platelet count dose-dependently
(Erickson-Miller et al., 2005, 2009; Jenkins et al., 2007). The
treatment of chronic idiopathic thrombocytopenic purpura (ITP)
or chronic hepatitis C patients with eltrombopag effectively
increased platelet number and reduces thrombocytopenia-
related complications (Bussel et al., 2007, 2009; McHutchison
et al., 2007).
Eltrombopag is only capable of activating parts of the c-Mpl
signaling pathways, but whether eltrombopag retains the
function of TPO in enhancing stem cells and early progenitor
cells remains largely unknown (Erhardt et al., 2009; Will et
al., 2009). As eltrombopag is a c-Mpl agonist, we hypothe-
size that eltrombopag can expand HSCs and HPCs of UCB,
thus can enhance multi-lineage hematopoiesis. Given the
species specificity of eltrombopag to only humans and
chimpanzees, our investigation utilized an in vitro serum-
free culture system, and an in vivo NOD/SCID xenotrans-
plant model. Here we present results of our investigation of
eltrombopag in promoting multi-lineage hematopoiesis
through the expansion of bone marrow HSCs and HPCs of
human UCB in vivo using the NOD/SCID human bone marrow
xenotransplant model. We further examined eltrombopag's
effects on the expansion of human UCB CD34+ CD38− cells in
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between eltrombopag and TPO on the HSCs/HPCs and the
intracellular phosphorylation of STAT5, STAT3, and AKT
pathways.
Results
Eltrombopag promoted multi-lineage hematopoiesis
of engrafted human UCB CD34+ cells in NOD/SCID
mice
We examined effects of eltrombopag on hematopoiesis of
human UCB CD34+ cells transplanted in sublethally irradiated
NOD/SCID mice. The mice were gavaged with eltrombopag
daily (50 mg/kg/day) vs. vehicle for 28 days, starting one-day
post-human UCB CD34+ cell transplantation. Day-zero was
defined as the day of humanUCB transplantation. Eltrombopag
treatment significantly promoted thrombopoiesis (Fig. 1A),
leading to a 3.6 fold increase in circulating human platelets
between weeks 4 and 5 when compared with vehicle treated
mice. In addition, eltrombopag treatment significantly in-
creased the circulating human white blood cells (WBCs) at
week 5 (Fig. 1C). Note that eltrombopag had no effect on
murine thrombopoiesis (Fig. 1B), nor murine WBC counts
(Fig. 1D). As the progenitors for thrombopoiesis and for WBCs
are from different HPC lineages, our observation supported
that eltrombopag promoted multiple lineage proliferation and
differentiation of human UCB CD34+ cells. By week 9, which
was 5 weeks after cessation of eltrombopag treatment, theFigure 1 Eltrombopag treatment increased circulating human pla
after transplantation. The mice were transplanted with human UCB
vehicle daily for 28 days. (A) Human platelets. (B) Mouse platelets. (C
±standard error of the mean (n=8–12). *pb0.05, **pb0.01 betweennumber of human platelets as well as WBCs in the drug-treated
NON/SCID mice was still higher than those in the vehicle-
treated mice, although the differences were not statistically
significant due to variations among mice in the same treat-
ment group.Eltrombopag enhanced expansion of HSCs/HPCs of
human UCB CD34+ cells in the bone marrow of
NOD/SCID mice
To assess if the increase of peripheral human platelets and
WBCs is a result of eltrombopag's effect on human HSCs and
HPCs in the bone marrow compartment of NOD/SCID mice, we
examined the cell surface markers of cells extracted from the
bone marrow of NOD/SCID mice. We found that bone marrow
human CD45+ (marker for WBC lineage), CD34+ (marker for
HSC/HPC) and CD41+ (marker for thrombocyte lineage) cells
were augmented by eltrombopag treatment. Eltrombopag-
treated mice had 1.6 and 2 fold more bone marrow CD45+ on
week 3 (pb0.01) and week 4 (pb0.01), respectively (Fig. 2A).
By week 9, which was 5 weeks after cessation of eltrombopag
treatment, the number of human CD45+ bone marrow cells
was still significantly higher (70%) than that in the control
mice. For HSC/HPC, there was 70% increase of bone marrow
CD34+ cells in the eltrombopag-treated group as early as week
1 (pb0.05) (Fig. 2C), with further increase to more than 150%
on week 2 (pb0.01) and week 4 (pb0.05). For thrombopoiesis,
the administration of eltrombopag induced a 1.8 fold increase
in human CD41+ bone marrow cells by the end of 4-weektelets and human WBCs in peripheral blood of NOD/SCID mice
CD34+ cells. Mice were gavaged with 50 mg/kg eltrombopag or
) Human WBCs and (D) mouse WBCs. Data are expressed as mean
eltrombopag and vehicle two-tail Mann–Whitney's U test.
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CD41+ bone marrow cells in the mice treated with eltrombo-
pag at week 9, though the differences were not statistically
significant. Again, eltrombopag did not affect the proliferation
of mouse CD45+ bone marrow cells (Fig. 2B).
Eltrombopag enhanced expansion of human CD34+
CD38− cells in vitro
It is known that human HSCs are highly enriched in the CD34+
CD38− fraction, and the measure of CD34+ CD38− is a close
estimate of HSCs (Bhatia et al., 1997; Larochelle et al.,
1996). To further expand on our observation that eltrombo-
pag promoted expansion of bone marrow HSC/HPCs in the
NOD/SCID xenotransplant model, we conducted assessment
of eltrombopag's effect on the expansion of HSCs/HPCs using
a well-defined, serum-free culture system for UCB. Eltrom-
bopag's effects on promoting proliferation vs. differentiation
of human UCB were compared with the rhTPO effects in
vitro. Human UCB CD34+ cells were cultured in serum-free
medium supplemented with rhSCF and rhFL plus either
rhTPO or eltrombopag for 7 days. Human CD34+ CD38− cells
(more primitive cell population) were measured along with
all cells expressing CD34+ and cells expressing CD41+, the
marker for megakaryocytes and other HPCs committed to
thrombopoiesis. Scatter plots of cell marker phenotypes
were analyzed by flow cytometry, and are shown in Fig. 3A.
The cell number (bars) and percentage (squares) areFigure 2 Eltrombopag promoted rapid establishment of hum
transplantation. The mice were transplanted with human UCB CD
vehicle daily for 28 days. (A) Human CD45+ bone marrow MNCs. (B) M
MNCs. (D) Human CD41+ bone marrow MNCs. Data are expressed as m
between eltrombopag and vehicle two-tail Mann–Whitney's U test.presented in Fig. 3B. Compared to the control culture (SF)
of rhSCF and rhFL only, the addition of 3 μg/ml eltrombopag
significantly increased CD34+ cells by 26%, CD34+ CD38−
cells by 42%, and CD41+ cells by 400%. In comparison, the
cultures containing 10 ng/ml rhTPO (SFT10) had significantly
increased CD34+ cells by 130%, CD34+ CD38− cells by 160%,
and CD41+ cells by 900%. The increase in rhTPO concentra-
tion from 10 ng/ml to 50 ng/ml did not lead to more
expansion, supporting that the effect of rhTPO was saturated
at 10 ng/ml. The “percentages” (squares) of CD34+, CD34+
CD38− and CD41+ cells were almost the same in the cultures
with 10 ng/ml rhTPO vs. 3 μg/ml eltrombopag. Thus, our
data support that rhTPO supported greater cell proliferation
than eltrombopag, while the extent of cell differentiation
induction, maintaining primitive hematopoietic progenitors,
and promotion of megakaryopoiesis are almost the same
between eltrombopag and rhTPO. We also noted that the
increase of eltrombopag from 3 μg/ml to 6 μg/ml inhibited
proliferation in all cell populations and almost eliminated
CD41+ cells, showing the potential toxicity of eltrombopag at
higher concentrations.
Eltrombopag induced phosphorylation of STAT5, but
not STAT3 and AKT
To gain insight into potential differences between eltrom-
bopag and rhTPO in the activation of intracellular signaling
pathway related to the activation of TPO receptor c-Mpl, wean engraftment in bone marrow of NOD/SCID mice after
34+ cells. Mice were gavaged with 50 mg/kg eltrombopag or
ouse CD45+ bone marrow MNCs. (C) Human CD34+ bone marrow
ean±standard error of the mean (n=7–12). *pb0.05, **pb0.01
Figure 3 Expansion of human UCB CD34+ cells in the culture. Human UCB CD34+ cells (N90% purity) were cultured in the presence
of 25 ng/ml SCF (S), 50 ng/ml FL (F) and 10 or 50 ng/ml rhTPO (T10 or T50) or 0.5, 3, 6 μg/ml (equivalent to 1.13, 6.78 and 13.6 μM,
respectively) eltrombopag (E0.5, E3 or E6) for 7 days. The cells were counted and analyzed by flow cytometry. (A) The population
distribution after the 7-day culture by flow cytometry. (B) The numbers of total viable cell, CD34+, CD34+ CD38− and CD41+ cells are
presented in bar graph, while their percentages are shown as squares. 1×105 CD34+ human UCB cells were seeded in the beginning of
the culture. Data are showed as mean±standard error of the mean, n=3–5. Compared with the control culture (SF), *pb0.05,
**pb0.01 by two-sided paired t-test.
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and AKT pathways after treatment with rhTPO vs. eltrom-
bopag (Fig. 4). The analysis was flow-cytometry-based
assay, which offered the advantage of analyzing phosphor-
ylation of the target proteins at the single cell level. Three
cell types: CD34+ CD41−, CD34− CD41+, and CD34− CD41−
(Fig. 4A) were gated to measure the levels of pSTAT5,
pSTAT3, and pAKT in these cells after treatment by either
eltrombopag or rhTPO. We first analyzed the TPO-R levels of
these three cell types. Our culture condition contained rhSCand rhFL to enrich TPO-R (c-Mpl) expression for the
investigation of intracellular signal pathways, and we
achieved an average of 97%±2% of cells expressing TPO-R.
We found that expression levels of TPO-R were not different
in these three different cell populations at all time points for
the untreated control, the eltrombopag treated group, and
the rhTPO treated group (Fig. 4B, last row of panels). After
gating the cells, less than 0.1% of extreme outliers of
fluorescence intensity were gated away and the mean of
fluorescence intensity was calculated (Fig. 4B). Both rhTPO
Figure 4 Phosphorylation of STAT3, STAT5 after treatment with rhTPO or eltrombopag. Human UCB CD34+ cells were expanded in
serum-free media with 50 ng/ml FL, 25 ng/ml SCF, and 10 ng/ml rhTPO for 7 days. Then the cells were rendered quiescent in serum-
free media without cytokines for 7–8 h. The cells were exposed to 100 ng/ml rhTPO or 3 μg/ml eltrombopag for 10 to 60 min at 37 °C.
These cells were then fixed, permeabilized, stained for surface markers and intracellular antigens, and analyzed by flow cytometry.
(A) Cell population gating. (B) Phosphorylation of STAT3, STAT5 and AKT in CD34+ CD41−, CD34− CD41+ and CD34− CD41− cells
induced by rhTPO or eltrombopag. Data are shown as mean±standard error of the mean, n=4. Compared with the untreated control,
*pb0.05, **pb0.01 by two-sided paired t-test. (C) Almost all cells expressed TPO receptors (TPO-R) after 7-day culture. The close
curve shows the cells stained with anti-TPO-R (anti-c-Mpl) antibody, while the open curve represents the cells stained with isotype
antibody for non-specific and background binding.
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STAT5 in CD34+ CD41−, CD34− CD41+, and CD34− CD41−
cells when compared with untreated control. Eltrombopag
and rhTPO induced STAT5 phosphorylation to the same
extent in CD34+ CD41− and CD34− CD41− cell types, while
rhTPO induced significantly more phosphorylation of STAT5
in CD34− CD41+ cells than eltrombopag at all time points
(pb0.05, two-sided paired t-test). In contrast to rhTPO, the
level of eltrombopag induced phosphorylation of CD34+
CD41−, CD34+ CD41+, and CD34− CD41− cells were compa-
rable among all three cell-types (Fig. 4, first row of panels).
For STAT3 and AKT pathways, we observed that phosphor-
ylation of STAT3 and AKT was not increased by eltrombopag
in these three cell types, while rhTPO did increase phosphor-
ylation of STAT3 and AKT in CD34− CD41+ cells, but not in
CD34+ CD41− and CD34− CD41− cells. The cell-type depen-
dant phosphorylation of STAT5, STAT3, and AKT induced by
rhTPO was not caused by any difference in the level of TPO-Rexpression. Eltrombopag differed from rhTPO in the lack of
inducing phosphorylation of pSTAT3 and AKT in “more
committed progenitor cells”. Such observations highlighted
the target cell-type differences of eltrombopag vs. rhTPO,
and the potent effects of TPO on megakaryopoiesis.Discussion
In the stem cell transplantation setting, reconstitution of
bone marrow and the subsequent recovery of peripheral
blood cells are dependent on the expansion and differenti-
ation of the HSCs and HPCs of donor cells. In this report, we
investigated eltrombopag's effect on human UCB CD34+ cells
in the NOD/SCID mice xenotransplants after receiving human
UCB CD34+ cells. We found that eltrombopag treatment
accelerated expansion of human CD34+ progenitors, human
CD45+ and CD41+ cells in the bone marrow, and promoted
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without any influence on mouse hematopoietic cells (Figs. 1
and 2). By week 9, which was 5 weeks after the cessation of
eltrombopag feeding, the differences between the eltrombopag-
treated mice and the control mice persisted. The multiple
lineage and long-term effect of eltrombopag strongly suggested
that it acted on “earlier hematopoiesis” at the HSC/HPC levels
in addition to its anticipated effect on promoting megakar-
yocpoiesis, which is a more committed later stage.
To further examine eltrombopag's effect on early hemato-
poiesis through HSCs/HPCs, we tested the ability of eltrombo-
pag on the expansion of human UCB CD34+ cells in the presence
of SCF and FL in the serum-free media (Fig. 3). Eltrombopag
significantly expanded CD34+ CD38− HSCs/HPCs, CD34+ imma-
ture progenitors and CD41+ cells. In comparison with the
effects of 3 μg/ml eltrombopag, 10 ng/ml rhTPO did not affect
the percentage of CD34+ CD38−, CD34+, and CD41+ cells but
did markedly increase the expansion, supporting the fact that
eltrombopag is as effective as TPO in regulating the balance of
proliferation and differentiation among CD34+ CD38−, CD34+,
and CD41+ cells. However, eltrombopag was not as potent as
TPO in promoting proliferation. Our finding was consistent with
a recent report showing that eltrombopag was able to expand
CD34+ CD38− cells in the presence of SCF in the serum-free
culture (Nishino et al., 2009), suggesting that it at least partly
retained the function of TPO on early hematopoiesis.
The differential findings between eltrombopag and TPO
suggested the possibility that separate intracellular signaling
pathways might have taken place in mediating proliferation vs.
differentiation of HSC/HPCs mediated by c-Mpl. To look for the
potential mechanisms behind the functional difference be-
tween TPO and eltrombopag, we conducted a cytometry-based
method to analyze the phosphorylation of STAT3, STAT5 and
AKT in the signaling pathway of TPO receptor (c-Mpl), in three
different cell types: CD34+ CD41− HSC/HPC, CD34− CD41+
megakaryocytes, and CD34− CD41− cells. We found that the
level of phosphorylation of STAT5 induced by eltrombopag was
similar in all three cell-populations andwere comparable to the
level stimulated by TPO in CD34+ CD41− and CD34− CD41−
cells, but TPO stimulated higher levels of STAT5 phosphoryla-
tion in CD34− CD41+ cells. This was the cell population that was
more committed to thrombopoiesis than the other two cell
type populations. We also observed that TPO activated STAT3
and AKT in CD34− CD41+ cell, while eltrombopag did not cause
the phosphorylation of STAT3 and AKT pathways in CD34−
CD41+ cells. Because eltrombopag promoted CD41+ differen-
tiation as effectively as TPO in our in vivo model, our finding
suggested that STAT3 and AKT signaling pathway might not be
important for the differentiation of CD34+ cells to CD41+ cells.
It is known that the binding of TPO to c-Mpl activates MAPK
p42/p44, AKT, and STAT proteins in normal human CD34+ cells,
megakaryocytes, and platelets (Majka et al., 2000, 2002),
while eltrombopag activates MAPK p42/p44 and STAT5 in N2C-
TPO cells, and STAT5 in human megakaryocytes (Erickson-
Miller et al., 2009). In human platelets, eltrombopag induces
STAT1, STAT3, and STAT5 activation, but spares AKT phosphor-
ylation (Erhardt et al., 2009). In bone marrow cells from
patients with acute myeloid leukemia and myelodysplastic
syndrome, eltrombopag activates STAT5 but not STAT3 (Will et
al., 2009). Combining our findings with the published reports
support the observation that the activation of the downstream
signaling pathway by eltrombopag differs from TPO, despitethe fact both exert their functions through the TPO-R (c-Mpl)
binding.
To our knowledge, our manuscript is the first of its kind in
finding that the thrombopoietic agent, i.e., eltrombopag, has
the potential to expand UCB CD34+ “in vivo”. The implication
is significant in that despite much work has been done on “ex
vivo” UCB CD34+ cell expansion, the current success rate of
UCB stem cell transplantation remains poor when compared
with PBSC transplantation or bone marrow stem cell trans-
plantation. If eltrombopag can improve UCB transplant
directly in vivo, which will need to be tested in future clinical
trials, it potentially can either negate the need of “ex vivo”
UCB stem cell expansion procedures, or may work synergisti-
cally with “ex vivo” expansion of UCB CD34+ cells to enhance
UCB transplant success rate.Conclusion
Our in vivo data demonstrated that eltrombopag was
effective in accelerating the expansion of human UCB
CD34+ HSCs/HPCs and in promoting multi-lineage hemato-
poiesis in the animal human bone marrow xenotransplant
model. The in vitro data further supported eltrombopag
effects on the proliferation of CD34+ CD38− primitive
progenitors in the serum-free culture. In vitro studies also
delineated the effects of eltrombopag vs. TPO on different
cell populations in the induction of intracellular signaling
pathways. Our data suggests that eltrombopag at least
partly retains the function of TPO on early hematopoiesis,
and appears to have fewer effects on intracellular signaling
in the more committed (CD41+) progenitor cell population.
Our finding has the potential in clinical applications to
improve the success rate of UCB transplantation by enhanc-
ing engraftment of human UCB for stem cell transplantation.Materials and methods
NOD/SCIDmouse for human cord bloodxenotransplant
Due to species specificity of eltrombopag in humans and
chimpanzees, the in vivo study was conducted using NOD/SCID
mice transplanted with human UCB. All animal experimenta-
tion protocols were approved by the University Committee on
Animal Resources at the University of Rochester. NOD/SCID
mice (Jackson Lab) were maintained under specific pathogen-
free conditions, and were provided with sterile water contain-
ing Sulfatrim. Nine to 10 week old mice were sublethally
irradiated with 3.5 Gy total body irradiation (TBI) using a Cs137
source to partially ablate mouse bone marrow cells. One day
after TBI, cryopreserved human UCB CD34+ cells (Stemcells)
were thawed and washed with IMDM supplemented with 10%
heat-inactivated FBS. Human CD34+ cells at 1×105 were
intravenously inoculated into the mice through the tail vein.
The mice received daily gavage of eltrombopag for 28 days at
the dose of 50 mg/kg in sterile water or vehicle (sterile
water), starting one-day after UCB transplantation. The dose
50 mg/kg/day was chosen based on the renal toxicity
information of mice in the dose range between 25 mg and
75 mg/kg/day (Eltrombopag Investigator Brochure, 2012).
Mice were sacrificed at 1, 2, 3, 4, 5, and 9 weeks from the
84 H. Sun et al.starting day of eltrombopag treatment. Whole blood was
drawn by cardiac puncture for cell counts. Bone marrow cells
were extracted by flushing femurs and tibia. Complete blood
counts and bone marrow mononuclear cell counts were
obtained using Heska HemaTure Hematology Analyzer and
FACSCalibur flow cytometer.
Analysis of human UCB engraftment in NOD/SCID
mice
To detect human cells in murine peripheral blood, multi-
color flow-cytometry analysis was performed using FACSCa-
libur flow cytometer (BD Biosciences). Human platelets were
differentially detected by staining whole blood with anti-
human CD41a-PE and anti-mouse CD61-FITC antibodies.
CountBright Absolute Counting Beads (Molecular Probe)
were added to samples as internal counting control to obtain
the number of platelets. Human WBCs were examined by
staining whole blood with anti-human-CD45-FITC and anti-
mouse CD45-PE antibodies. The RBCs were then depleted by
FACS lysing solution (BD PharMingen). The Draq5 (Biostatus)
was added at the final concentration of 2 μM and incubated
at room temperature for 5 min to stain the mononuclear
cells before the cells were subjected to analysis with
FACSCalibur. The percentage of human CD45+ WBCs in
total WBCs was measured by the cytometry. The number of
human CD45+ WBCs was calculated by multiplying the
percentage of human CD45+ WBCs in total WBCs with the
number of total WBCs measured by the Heska HemaTure
Hematology Analyzer. The bone marrow cells were stained
either with anti-human CD45-FITC and anti-mouse CD45-PE
antibodies or anti-human CD34-FITC and anti-human CD41a-
PE antibodies. Draq5 was used to stain MNCs and excluded
RBCs. The number of subpopulation was calculated by
multiplying the percentage of the population in total MNCs
measured by flow cytometry with the number of bone
marrow total MNCs. The antibodies were purchased from BD
or eBioscience.
Human UCB CD34+ cell in serum-free culture
The human UCB CD34+ cells with more than 90% purity
(Stemcells) were plated at 5×104 cells/ml in HPGM serum-
free media (Lonza) and cultured for 7 days at 37 °C in
humidified air with 5% CO2. rhTPO or eltrombopag at different
concentrations was added with 25 ng/ml recombinant human
SCF and 50 ng/ml recombinant human FL. On the fourth day,
the culture was diluted 1:1 with fresh medium containing the
cytokines. The cells were harvested on the seventh day. The
viable cells were distinguished by Trypan blue and counted
using a hemacytometer (Hausser Scientific, Horsham, PA).
Cells were stained with anti-human CD41, anti-human CD34
and anti-human CD38 before analyses using FACSCanto II.
Propidium iodide (Sigma) was added before flow sample
running to exclude the dead cells.
Phosphorylation STAT3, STAT5 and AKT
signaling pathway
We applied modified flow cytometric phospho-protein analysis
(Will et al., 2009) to measure the phosphorylation status ofSTAT3, STAT5 and AKT in the c-Mpl signal pathway of different
cell types. Human UCB CD34+ cells were cultured in the serum-
free media with 25 ng/ml rhSCF, 50 ng/ml rhFL and 10 ng/ml
rhTPO for 7 to 8 days. The cells were then washed with fresh
medium twice and 7 to 8 h serum starvation was allowed in the
HPGM serum-free medium. Cells were then treated with
100 ng/ml rhTPO or 3 μg/ml eltrombopag for 10 to 60 min at
37 °C. At the end of treatment, the cells were immediately
fixed by adding 1:1 (vol:vol) BD cytofix fixation buffer (BD
Bioscience) and incubated at 37 °C for 10 min. Cells were then
washed and permeabilized with BD phosphoflow Perm Buffer III
for 30 min on ice. The cells were washed again and stainedwith
anti-phospho-STAT3 (pY705), anti-phospho-STAT5 (pY694),
anti-phospho-AKT (pS473), anti-human CD41, anti-human
CD34, and anti-human TPO-receptor (c-Mpl) (allophycocyanin
(APC)-conjugated mouse monoclonal anti-human Thrombo-
poietin R antibody, R&D Systems Inc., Minneapolis, MN). The
stained cells were analyzed using FACSCanto II flow cytometer
(BD Biosciences).
Statistical analysis
Data are presented as the mean±standard error of the
mean. The difference between two groups of data in the
experiments of xenotransplantated NOD/SCID mice was
analyzed by nonparametric two-tail Mann–Whitney's U test,
as data were not normally distributed. In all other cases, two
groups of data were compared by two-sided paired t-tests.
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